USANA Health Sciences Inc (NYSE: USNA) has reported earnings for its second fiscal quarter (ending June 30) of $0.55 versus $0.89 for the same period a year ago — a decline of -38%. This result fell short of the consensus estimate of $0.65 by $-0.10. For the latest four quarters through June 30, E.P.S. were $2.87 versus $3.29 for the same period a year ago — a decline of -13%.
Recent Price Action
USANA Health Sciences Inc (NYSE: USNA) stock declined slightly by -0.5% on 7/23/24. The stock closed at $45.96. Moreover, above average trading volume at 132% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months but has risen 1.6% during the last week.
Current PriceTarget Research Rating
USNA is expected to continue to be a Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
USANA Health Sciences has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. USANA Health Sciences has a neutral Appreciation Score of 50 but a poor Power Rating of 29, resulting in the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment